Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting in San Antonio

The American Society for Radiation Oncology (ASTRO) announced today the 10 studies that will be highlighted in the 2022 ASTRO Annual Meeting press program. Researchers will discuss their findings in two news briefings to be held October 24 and 25 in the Henry B. Gonzalez Convention Center in San Antonio and via live webcast. Reporters can register for the meeting at astro.org/annualmeetingpress.

Low long-term risk of breast cancer recurrence after nipple-sparing mastectomy

Nipple-sparing mastectomy (NSM) – an increasingly popular option for women undergoing treatment for breast cancer – not only achieves good cosmetic outcomes, but also low long-term risk of recurrent breast cancer, reports a study in the October issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Breast Cancer Expert: “Awareness and Early Detection Save Lives”

One in eight women will be diagnosed with breast cancer in her lifetime.    For those with BRCA1 and BRCA2 gene mutations, the chances are even higher. The National Breast Cancer Foundation estimates that 55 to 65% of women with the BRCA1 mutation, and 45%…

MD Anderson Research Highlights for September 28, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include an investigation into the efficacy of dexamethasone for dyspnea relief, a combination therapy for hairy cell leukemia, an analysis of RAS mutations and their prognostic value in acute myeloid leukemia (AML), a possible new combination therapy for basal-like breast cancer, and swallowing exercises to improve the quality of life for patients with head and neck cancer undergoing radiotherapy.

UTHealth Houston study: Lower cancer screening rates differ by region, tied to social vulnerability

Populations in U.S. counties defined as more vulnerable based on social factors including socioeconomic status and racial/ethnic minority status were significantly less likely to receive timely breast, cervical, and colorectal cancer screenings, according to research from UTHealth Houston.

Susan G. Komen® Expands Breast Cancer Screening and Diagnostics Program

Susan G. Komen®, the world’s leading breast cancer organization, is expanding its screening and diagnostics program from nine cities to 12. Now, income-eligible residents from Dallas, Los Angeles, and Memphis also can access no-cost, breast cancer screening and diagnostic services. Atlanta, Chicago, Fort Worth, Houston, Madison, WI, Marshfield, WI, Philadelphia, Virginia Beach, and Washington D.C. are the other cities where the program is already operating.

Shape-shifting fat cells fuel breast cancer growth

Fat cells, or adipocytes, that grow in close proximity to breast cancers can shift into other cell types that promote tumor growth, a new study by UT Southwestern researchers suggests. The findings, published in Cell Reports, could lead to new ways to fight breast cancer, a disease that is diagnosed in more than 300,000 U.S. women each year and kills nearly 45,000 annually.

Scientists Identify Unique Breast Cancer Cells That Control Their Ability to Proliferate and Colonize the Lungs

Scientists from The Tisch Cancer Institute have uncovered a mechanism by which certain breast cancer cells regulate their own metastases, fuel dissemination from the original tumor site, and determine routes to invade distant organs such as the lungs, according to a study published in Cell Reports in September.

Technique Developed in Mice Could Aid Detection of Cancer in Dense Breasts

A two-pronged approach to imaging breast density in mice, developed by researchers at Georgetown Lombardi Comprehensive Cancer Center, resulted in better detection of changes in breast tissue, including spotting early signs of cancer. The researchers hope that this approach will be translated from mice and improve breast imaging for people; it may also help with prognosis of disease as density can be linked to specific patterns of mammary gland growth, including signs of cancer development.

HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment

Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology (ESMO) Congress 2022.

MD Anderson Research Highlights: ESMO 2022 Special Edition

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features upcoming oral presentations by MD Anderson researchers at the European Society for Medical Oncology (ESMO) Congress 2022 focused on clinical advances across a variety of cancer types. Highlights include promising early data from a novel T cell therapy for solid tumors, targeted therapy progress in rare and advanced cancers, biomarkers of immunotherapy response, and features associated with clinical outcomes in leptomeningeal disease. More information on ESMO content from MD Anderson can be found at MDAnderson.org/ESMO.

Prompt Recognition and Treatment Found Effective for Lung Disease in Patients Who Received New Drug for Advanced Cancer

Lung disease caused by a new drug for cancers—including metastatic or advanced breast cancer—can be effectively treated using approaches that focus on early detection and prompt management, according to a study published in ESMO Open on August 11, 2022.

NCCN Publishes New Patient Guidelines for Breast Cancer Screening and Diagnosis Emphasizing Annual Mammograms for All Average-Risk Women Over 40

The National Comprehensive Cancer Network (NCCN) has published new NCCN Guidelines for Patients: Breast Cancer Screening and Diagnosis to help people understand their personal risk for breast cancer, when they should begin screening, and how often to screen—in order to detect cancer earlier, for more treatment options and better outcomes.

Enhancing Awareness and Participation of Black Breast Cancer Patients in Clinical Trials

Coral Omene, MD, PhD, medical oncologist in the Stacy Goldstein Breast Cancer Center at Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center together with RWJBarnabas Health, has been awarded a $50,000 grant from the V Foundation for Cancer Research in partnership with ESPN to increase clinical trial awareness and enrollment of Black women with breast cancer.

MD Anderson Research Highlights for July 13, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targets involved in protecting DNA replication forks and preventing inflammatory responses, a new treatment option for elderly patients with late-stage acute myeloid leukemia, insights into the breast cancer tumor microenvironment, biomarkers of response to targeted and immune therapies, a novel cellular therapy option for osteosarcoma and a new target for inducing ferroptosis in cancer cells.

MD Anderson Research Highlights for June 29, 2022

The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a lower-intensity therapy for acute myeloid leukemia, a new target for treating chronic myelomonocytic leukemia, real-world synthetic controls for clinical trials in rare cancers, a potential biomarker to predict endocrine therapy response in breast cancer, integrated CRISPR screens to identify novel tumor suppressors, and a deeper knowledge of the immune tumor microenvironment in melanoma-derived brain metastases.

Brooke Emerling awarded $2.3 million to demystify breast cancer metabolism

Brooke Emerling from Sanford Burnham Prebys has been awarded a new grant from the National Institutes of Health (NIH) to continue her work on cellular signaling in cancer. The four-year, $2.3 million project could accelerate the development of new therapies for a range of cancers, particularly metastatic breast cancer. It also offers an answer to a longstanding mystery in cancer metabolism.

SUSAN G. KOMEN® INVESTS $21.7 MILLION IN RESEARCH FOCUSED ON IMPROVING OUTCOMES FOR BREAST CANCER PATIENTS

Susan G. Komen® is awarding $21.7 million to fund 48 new research projects at 26 distinguished academic medical institutions in the U.S. that are focused on improving patient outcomes – particularly for people with the most aggressive breast cancers, or who have experienced a recurrence or metastasis.

JNCCN: Mismatch in Breast Cancer Trial Results and Real-World Outcomes Based on Treatment Discontinuation

New population study in JNCCN on adjuvant hormone therapy for breast cancer finds correlation between hot flashes and poorer outcomes—in contrast to clinical trial results; likely due to patients with side-effects ending treatment early.

New Perspective Shows Higher Breast Cancer Mortality for Black Women Emerged 40 years ago

A new perspective by researchers from the American Cancer Society and the University of Texas Health Science Center at San Antonio shows the high burden of breast cancer mortality in African American (Black) women versus White women began in the United States in the 1980’s.

Chemicals in personal care products cause harmful effects in breast cancer cells from Black women

Chemicals called parabens, which are found in widely used hair and personal care products, cause harmful effects in breast cancer cells from Black women, according to a new study being presented Sunday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Probiotic bacteria may enhance tamoxifen effectiveness in treatment of ER+ breast cancer

Probiotic bacteria may enhance anti-cancer activities of the breast cancer drug tamoxifen and other endocrine-targeted therapies, which could help reduce the risk of estrogen receptive positive (ER+) breast cancer, suggests a new study presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability

A compound synthesized by a team led by UT Southwestern scientists kills a range of hard-to-treat cancer types by targeting a previously unexploited vulnerability, a new study reports. The findings, published in Nature Cancer, could eventually lead to new drugs to fight these cancers, which currently have few effective treatments.

UCSF and I-SPY 2 Breast Cancer Researchers Develop Newly Redefined Breast Cancer Response Subtypes

Research scientists and statisticians from UC San Francisco have developed improved biomarker classifications as part of their research results in the I-SPY 2 trial for high-risk breast cancer patients. The new cancer response subtypes reflect responsiveness to drug treatments and are intended to help clinicians be more precise in how they target therapies.

Henry Ford Health is First in the World to Offer Latest Advancement in MR-Guided Radiation Therapy

Henry Ford Health is the first in the world to complete a full course of patient treatments using the latest advancement in magnetic resonance (MR)-guided radiation therapy, which integrates real-time magnetic resonance imaging (MRI) and linear acceleration to deliver precise and accurate radiation treatment more rapidly than ever before.

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment

Research from the University of Michigan Rogel Cancer Center could provide a new approach to treating an aggressive form of breast cancer. A study led by Duxin Sun, Ph.D., found that targeting the immune microenvironment in lymph nodes and tumors simultaneously led to long-term tumor remission in mice models of metastatic triple negative breast cancer.

Moffitt Researchers Identify Pathway that Regulates Lipid Synthesis and Contributes to Tumor Survival

In a new study published in the journal Cell Reports, Moffitt Cancer Center researchers show that cancer cells in an acidic environment undergo lipid synthesis and accumulation. The team identified the key signaling molecules responsible for these changes and discovered that these alterations are associated with poor outcomes and disease progression among breast cancer patients.

MD Anderson Research Highlights for May 4, 2022

Featured studies include clinical advances with a new combination therapy targeting angiogenesis in platinum-resistant ovarian cancer and a promising immunotherapy combination for kidney cancer, plus laboratory studies that focus on targeting ferroptosis in specific lung cancers, developing chimeric antigen receptor (CAR) T cell therapies for blastic plasmacytoid dendritic cell neoplasms, and characterizing racial and ethnic disparities in breast cancer early detection.